Experiments

Searchable full-text extractions: founding hypothesis, core claims, experimental setups, key results and statistics — pulled out of each paper as structure. Search a cell line, an assay or an entity (e.g. HUH7) and find every paper that worked with it. This corpus stands on its own: most entries carry no reproduction assessment (yet).

• Targeting Wnt/β-catenin and circadian regulator restores PRC2/EZH2-controlled chromatin bivalency and suppresses cell state diversity.

  PMID 41842971 · PMC13132380 · The Journal of clinical investigation · 2026 · 8 claims · 8 setups

  Full-text index only

  PRC2i/EZH2i alone or combined with AR inhibitors induce diverse cell state programs (CSPs) that increase tumor cell invasion, metastasis, and drug resistance despite only modest suppression of tumor growth.

  lncap pca pdx clinical viability tumor ic50

• SMARCA4/2 loss reduces BCL-xL expression and confers a druggable MCL1 dependency in cancer.

  PMID 41807550 · PMC13249849 · NPJ precision oncology · 2026 · 8 claims · 8 setups

  Full-text index only

  MCL1 inhibition is synthetic lethal with SMARCA4/2 loss in SCCOHT and NSCLC cells

  nsclc lung smarca4 bin-67 genome-wide drug colony